Skip to main content

Nivolumab

Question for Department of Health

UIN 10596, tabled on 17 September 2015

To ask the Secretary of State for Health, pursuant to the Answer of 14 September 2015 to Question 8491, whether interim commissioning arrangements are being considered for nivolumab lung cancer.

Answered on

14 October 2015

NHS England is aware that the National Institute for Health and Care Excellence is reviewing the use of nivolumab in lung cancer, and is likely to report shortly. NHS England has therefore advised that it intends to await the NICE recommendation rather than develop interim arrangements.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.